NanoViricides

NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoViricides, Inc. is a clinical stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

NanoViricides (NYSE-A:NNVC) said it believes that its broad-spectrum antiviral candidate, NV-387, could be a critical tool in combating a potential bird flu pandemic caused by the H5N1 Influenza A virus. In a statement, the company claims the virus would be unable to evade NV-387, even as it mutates.

NanoViricides sees NV-387 as a key defense against bird flu pandemic

SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug. "Despite all changes, the H5N1 Influenza A virus should remain susceptible to NV-387 because NV-387 mimics the very essential host-side feature that H5N1 continues to use even as it changes," said Anil R.

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

The rise of unexplained human cases of bird flu in North America means there is an urgent need for effective treatments that can withstand viral mutations. In this opinion article, Anil Diwan, CEO of NanoViricides (NYSE-A:NNVC), a clinical-stage nano-biopharmaceutical company that develops and commercializes drugs designed to treat viral infections, raises alarm over the evolving threat of H5N1 bird flu, highlighting recent research that shows the virus is just one mutation away from effectively targeting human cells.

NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America

NanoViricides (NYSE-A:NNVC) reported progress on its lead antiviral drug NV-387 and revealed plans to advance Phase II clinical trials for MPox and RSV. The Shelton, Connecticut-based company is waiting for results from its Phase I trial of NV-387 and has taken steps towards starting a Phase II trial of NV-387 for the treatment of MPox infection in Central Africa.

NanoViricides pushes NV-387 to Phase II trials

SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024 with the Securities and Exchange Commission (SEC) on Thursday, November 14, 2024. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000141057824001991/nnvc-20240930x10q.htm).

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D.

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

SHELTON, CT / ACCESSWIRE / October 22, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R.

NanoViricides President Dr. Diwan to Present at the PODD Conference

SHELTON, CT / ACCESSWIRE / October 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D.

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT / ACCESSWIRE / October 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D.

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

NanoViricides (NYSE-A:NNVC) filed its annual report, announcing that its broad-spectrum antiviral NV-387 is progressing to Phase II clinical trials, with potential indications including RSV, influenza, MPOX/smallpox, and COVID-19. NV-387 has demonstrated broad-spectrum efficacy in preclinical trials against viruses such as COVID-19, RSV, and influenza.

NanoViricides prepares for Phase II trials for antiviral NV-387

SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2024 with the Securities and Exchange Commission (SEC) on Friday, September 27, 2024. The report can be accessed at the SEC website ( https://www.sec.gov/ix?doc=/Archives/edgar/data/1379006/000141057824001650/nnvc-20240630x10k.htm ).

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

NanoViricides (NYSE-A:NNVC) announced that it has signed a Memorandum of Understanding (MOU) with TheraCour Pharma, granting it the right of first refusal on all antiviral drug developments. This agreement expands NanoViricides (NYSE-A:NNVC)' access to critical intellectual property, enhancing its ability to develop treatments for a wide range of viral infections.

NanoViricides expands antiviral drug pipeline with TheraCour Pharma agreement

SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it has now obtained a right of first refusal (ROFR) for all antiviral drug developments from the R&D firm TheraCour Pharma, Inc. ("TheraCour").

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

NanoViricides (NYSE-A:NNVC) CEO Anil Diwan joined Proactive to discuss the promise of its lead drug NV-387 as a broad-spectrum antiviral. Diwan explained that NV-387, a host mimetic drug, works differently from traditional antiviral treatments by mimicking a natural cellular feature, making it difficult for viruses to escape.

NanoViricides CEO talks lead drug asset's potential as MPOX therapy - ICYMI

NanoViricides (NYSE-A:NNVC) announced that it is investigating the potential use of its lead drug candidate NV-387 to treat MPOX patients under the World Health Organization's Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) protocol. This follows the organization's recent declaration of a Public Health Emergency due to the 2024 MPOX outbreak.

NanoViricides exploring emergency protocol to evaluate NV-387 for MPOX

SHELTON, CT / ACCESSWIRE / August 26, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it is investigating the possibility of using NV-387 for the treatment of MPOX patients under the WHO MEURI protocol, in light of the recent WHO PHEIC (Public Health Emergency of International Concern) declaration for the current 2024 MPOX outbreak that is rapidly spreading into more than ten countries in Africa with additional cases detected in Thailand and Sweden. MEURI, i.e.

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

Spectrum Pharma

NanoViricides (NYSE-A:NNVC) is advancing its clinical program with plans for an innovative Phase II trial of its drug candidate NV-387, the company announced Monday. The drug candidate NV-387, which has shown promise in treating various viral infections including RSV, COVID-19, and Influenza in animal studies, could revolutionize the treatment of respiratory viruses, according to the company.

NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387

SHELTON, CT / ACCESSWIRE / August 19, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update on its clinical program activities. Dr. Anil Diwan, the Company's President, and Executive Chairman, is currently visiting with various expert professionals with the objective of developing a Phase II clinical trial plan and corresponding clinical protocol for a Phase II clinical trial of the drug candidate NV-387.

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

NanoViricides (NYSE-A:NNVC) has highlighted significant progress made in advancing its lead drug candidate NV-387 during the 2024 fiscal year 2024, which ended June 30, in a letter to investors. NV-387 is designed to disable viruses by mimicking the host cell, targeting a wide range of viruses including Influenza, COVID, RSV, and more.

NanoViricides reports major progress in advancing broad-spectrum antiviral drug NV-387

SHELTON, CT / ACCESSWIRE / August 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update on its clinical program and strategy in this letter to investors. NanoViricides is developing a unique direct-acting antiviral drug that mimics the host cell and thereby is designed to disable the virus particle from infecting the cell.

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 2, 2024) - Investorideas.com, a go-to investing platform covering biotech and nanotechnology issues a snapshot looking at news and developments in the antiviral market, featuring NanoViricides, Inc. (NYSE American: NNVC), a development stage company that is creating special purpose nanomaterials for antiviral therapy. Read the full article on Investorideas.com https://www.investorideas.com/News/2024/nanotech/08020Better-Solutions-for-Viruses.asp From COVID to RSV and now Bird Flu, the global threat of viruses is only a headline away and there is a lot of profit for companies offering solutions.

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

NanoViricides (NYSE-A:NNVC) has announced the publication of two independent reports on the company by industry analysts which highlight the potential of its broad spectrum drug candidate NV-387 as a viral therapy. In a research note titled “NNVC: NanoViricides (NYSE-A:NNVC) Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy,” author Dr David Bautz of ZacksSCR described the antiviral asset NV-387 as “exciting.

NanoViricides' lead asset for broad spectrum efficacy wins praise in industry reports

SHELTON, CT / ACCESSWIRE / August 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports that two separate and independent research reports have been published by industry analysts on the Company. "NNVC: NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy," is the title of a new research note published by David Bautz, PhD, Zacks SCR, on July 31st, 2024.

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

NanoViricides (NYSE-A:NNVC) has highlighted the strong safety and efficacy of its lead clinical drug candidate NV-387 against coronaviruses. Animal studies of NV-387 have shown it can be “highly effective” in treating COVID infections.

NanoViricides spotlights lead drug candidate's potential as COVID therapy

SHELTON, CT / ACCESSWIRE / July 24, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today reminds the strong safety and effectiveness against coronaviruses demonstrated by its lead clinical drug candidate NV-387. "President Joe Biden has thankfully recovered from the bout of COVID caused by a new variant," said Anil R.

News for NanoViricides Stock (NNVC)